MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline

November 10, 2022

https://www.globenewswire.com/news-release/2022/11/10/2553381/0/en/MiNK-Presents-Clinical-Data-at-SITC-2022-Showcasing-iNKT-Cell-Therapy-Pipeline.html

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) —  MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the presentation of new data from five presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Read more at globenewswire.com

Related news for (INKT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.